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ABSTRACT
In the past few years several developments in medications have been 
made for the better treatment of certain diseases like Breast Cancer, 
Alzheimer’s disease, Tuberculosis, Obesity and Malaria. Phytochemicals 
possessing various medicinal properties have opened up the door to 
discover or design novel drug against these diseases. Syringic acid is 
such a natural compound found in many plants with a vast range of 
therapeutic potentials against several diseases. The present study 
aims to reveal Syringic acid as a potent inhibitor against Breast Cancer, 
Alzheimer’s disease, Tuberculosis, Obesity and Malaria comparing 
to the standard drugs of each disease. Molecular docking of syringic 
acid with critical proteins associated with the diseases was done 
using Schrödinger Maestro (v11.1). QikProp module of Schrödinger 
Maestro was used for ADME prediction and the toxicity of the ligand 
was evaluated by ProTox online databases. Syringic acid was found 
to exhibit acceptable ADME properties with no carcinogenicity and 
mutagenicity. Molecular docking result also showed higher scores 
compared to the commercially available standard drugs against 
four out of five diseases. The best docking scores were found against 
Breast cancer, Alzheimer’s disease, Obesity and Malaria which are 
-6.801 kcal/mol, -5.285 kcal/mol, -5.491 kcal/mol and -4.141 kcal/mol 
respectively. Syringic acid can be a stronger inhibitory potential agent 
against selected diseases than the standard drugs. Further clinical 
studies are required to consider syringic acid as an effective candidate 
drug for the better treatment of the mentioned diseases.
Keywords: Syringic acid, Molecular docking, ADME/T, In silico.
INTRODUCTION
Syringic acid is a phenolic compound which 
occurs in olives, dates, acai palm, grapes, pump-
kins, honey and many other plants.1,2 It exhibits 
many pharmacological properties including anti-
oxidant,  anti-inflammatory, anti-proliferative, 
 anti-microbial and anticancer activity.3,4 Along 
with these multi-pharmacologic activities of syrin-
gic acid, it can be considered for the evaluation as 
a novel drug against several diseases. Some diseases 
captured in this study are breast cancer, tuberculo-
sis, alzheimer’s disease, obesity and malaria.
Breast cancer is the most common cause of 
death due to cancer among women worldwide.5 
The treatments include surgery, radiotherapy, 
chemotherapy with antracycline, endocrine ther-
apy with tamoxifen and anti-HER2-therapy with 
trastuzumab.6 In case of tuberculosis, it is estimated 
that more than 8 million people suffer from TB 
each year and the death rate is approximately 2 
to 3 millions.7 Moreover, the rate is increasing due 
to multidrug-resistant strains of M. tuberculosis.8 
Similarly another infectious disease is Malaria that 
causes half a million deaths in 219 millions cases 
per year.9 Again, alzheimer’s disease a neurodegen-
erative disorder is responsible for 50-60% of the 
dementia cases.10 The risk of this disease increases 
substantially due to obesity.11
Molecular docking is a significant computa-
tional approach in lead optimization which predicts 
binding affinity between the selected compound 
and target protein. Therapeutic potential of any 
compound can be evaluated initially through 
molecular docking that ultimately saves time and 
cost in drug discovery. Since syringic acid possesses 
several types of activity, current study focuses on 
evaluating its pharmacologic properties against 
above mentioned diseases using computational 
approach.
MATERIALS AND METHODS
Ligand Preparation: The structure of Syringic acid 
(CID: 10742) was retrieved in SDF format from 
PubChem database (www.pubchem.ncbi.nlm.nih.
gov) and three-dimensional structure was prepared 
by using LigPrep wizard of Schrödinger maestro. 
Possible ionization state was generated using Epik 
at pH 7.0±2.0 for proper calculation of tautomer 
and better understanding of protonation state in 
biological condition.12 Up to 32 stereoisomers were 
generated per ligand retaining specific chiralities. 
Assigning the bond orders the structure was mini-
mized at OPLS3 force field.13 Similar methods and 
parameters are also used for the preparation of 
standard drug compounds for comparison purpose.
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Protein preparation: The receptors used for molec-
ular docking were downloaded from RCSB Protein 
Data Bank: 14 human estrogen receptor alpha (PDB 
id: 3ERT)15 against breast cancer, mycolic acid cyclo-
propane synthase(PDB id: 1KPI)16 against tubercu-
losis, BACE1 (PDB id: 4IVT)17 against Alzheimer’s 
disease, fat mass and obesity (FTO) protein (PDB 
id: 3LFM)18 against obesity and plasmepsin II (PDB 
id: 1SME)19 against malaria. Protein preparation 
wizard in Schrödinger Maestro (v11.1) was used for 
structure refinement of proteins where bond orders 
were assigned along with the addition of hydrogens 
to overwhelming atoms. Also the selenomethi-
onines were transformed into methionines and 
water molecules were deleted. Finally creating zero 
order bonds to metals and disulfide bonds, minimi-
zation was performed utilizing default constraint of 
RMSD 0.30 Å and force field OPLS3.
Active Site Selection: The active sites on target 
receptors were selected by PockDrug server which 
estimates pocket druggability using ligand proxim-
ity method.20 Setting proximity threshold to 5.5Å, 
the pocket with highest probability of druggability 
was selected.21
Receptor Grid Generation: In Glide, grids were 
generated maintaining the default parameters of 
van der Waals scaling factor 1.00, partial charges 
cutoff 0.25 and an OPLS3 force field. A bounding 
box for individual receptor was set to such extend 
that it covers the entire active site for docking 
experiment.
Docking Simulation: Standard precision ligand 
docking was performed in Glide of Schrodinger 
maestro (v11.1) where penalties were employed to 
non-cis/trans amide bonds. Van der Waals scaling 
factor and partial charges cutoff were set to 0.80 
and 0.15 respectively. Energy minimized posture 
was applied for final scoring and expressed as glide 
score. The poses and glide score value of syringic 
acid and standard drug compounds with each 
selected receptor was recorded.
ADME/T Analysis: ADME properties determine 
the drug-like activity of ligand molecule based on 
Lipinski’s rule of five.22 According to this rule, phys-
icochemical parameter ranges include molecular 
weight ≤ 500, H-bond donor ≤ 5, H-bond acceptor 
≤ 10, log P ≤ 5 and molar refractivity 40-130. The 
QikProp module of Schrödinger maestro (v11.1) 
was used to predict the absorption, distribution, 
metabolism and excretion (ADME) of syringic acid. 
Also the toxicity of the ligand was evaluated using 
SMILES (simplified  molecular-input  line-entry 
system) in ProTox online database.23 
RESULTS
Docking Simulation
In this study, molecular docking simulation was 
performed to analyze the interaction of syringic 
acid (Figure 1) with five receptors targeted for the 
treatment of specific diseases. Comparing to the 
standard drug, glide scores of syringic acid were 
tabulated in Table 1 and also, the interactions with 
bond distances were explained by analysis from 
Table 2. Hydrogen and hydrophobic interactions 
are displayed in Figure 1. Four out of five dock-
ing results of syringic acid have exhibited higher 
scores than standard drugs. Among them, the 
best result found was against breast cancer which 
is -6.801 kcal/mol. It forms two hydrogen bonds 
with Arg-394 and Glu-353 also three hydrophobic 
interactions with Leu-346, Ala-350 and Leu-387. 
Again, syringic acid possesses almost similar 
docking scores against Alzheimer’s disease and 
obesity which are -5.285 kcal/mol and -5.491 kcal/
mol respectively. When bound to BACE1 receptor, 
it forms two hydrogen bonds with Asp-32 and 
Phe-108 as well as two pi-pi stacking interactions 
with Phe-108 and Tyr-71. In case of fat mass 
and obesity (FTO) protein, amino acid Glu-234, 
Tyr-106 and Arg-96 was found in H-bonding 
interaction and His-231, Tyr-108 in hydrophobic 
interaction with syringic acid. The lowest dock-
ing score (-4.141 kcal/mol) obtained was when 
ligand binds to plasmepsin II by two H-bonds 
with Thr-217 and Asp-34 and a hydrophobic bond 
withVal-78 for anti-malarial activity. However, 
Table 1  Docking scores comparison between syringic acid and standard drugs
Diseases
Docking Scores (kcal/mol)
Syringic acid Standard Drugs
Breast cancer -6.801 -4.819 (Tamoxifen)
Tuberculosis -6.886 -7.016 (Thiacetazone)
Alzheimer’s Disease -5.285 -4.129 (Galantamine)
Obesity -5.491 -3.881 (Orlistat)
Malaria -4.141 -3.896 (Primaquine)
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this score is still higher than the standard drug 
selected for comparison. At last, the interaction 
that shows low docking score than standard drug 
is when syringic acid binds to the receptor mycolic 
acid cyclopropane synthase against tuberculosis. 
The interaction revealed a score of -6.886 kcal/mol 
forming two H-bonds with Tyr-24 and Tyr-41 also 
a pi-pi stacking with Phe-215. 
ADME/T Analysis
ADME property characterizes the drug-like activ-
ity of ligand molecules. Pharmacokinetic prop-
erties of syringic acid given in Table 3 show that 
the compound follow Lipinski’s rule of five. Also 
the predicted toxicity shows that the compound is 
non-carcinogenic and non-mutagenic.
DISCUSSION
Molecular docking provides information about the 
relative orientation of a ligand molecule when it 
is bound to a protein.24 Such information can be 
used to understand the pharmacological activity 
of natural compounds at biological condition and 
discover novel compounds with more potency and 
selectivity. From this aspect, in silico molecular 
docking study of syringic acid was carried out 
to analyze its mechanism of action against five 
diseases namely breast cancer, Alzheimer’s disease, 
tuberculosis, obesity and malaria. The study 
revealed that syringic acid possesses higher scores 
against four selected diseases when compared to 
the available standard drugs. The docked poses 
were further analyzed for interactions with amino 
acid residues of the receptor. Syringic acid was 
found to have shorter hydrogen bond interactions 
with the receptor active site which suggest that it 
has a stronger binding affinity. 
Furthermore, pharmacokinetic and toxicolog-
ical properties of a compound are the significant 
parameters in drug discovery process. Thus, syrin-
gic acid was subjected to the analysis of absorption, 
Table 3  Molecular properties of syringic acid
Molecular properties
Molecular weight 198.17 g/mol
Hydrogen bond donor 2
Hydrogen bond acceptor 5
High lipophilicity 1.02
Molar refractivity 48.41
Mutagenicity Non Mutagen
Carcinogenicity Non Carcinogen
Table 2  Interactions and bond distances of syringic acid with the receptor binding site
Diseases
Hydrogen bond interactions of Syringic acid Hydrophobic interactions of Syringic acid
Amino acid residue Distance (Å) Amino acid residue Distance (Å)
Breast cancer Arg-394 2.65 Leu-346 5.05
(PDB ID: 3ERT) Glu-353 1.60 Ala-350 5.04
- - Leu-387 5.24
Tuberculosis Tyr-41 1.84 Phe-215 4.09
(PDB ID: 1KPI) Tyr-24 2.02 -
Alzheimer’s Disease Asp-32 1.72 Tyr-71 5.52
(PDB ID: 4IVT) Phe-108 2.04 Phe-108 5.34
Obesity Glu-234 2.98 Tyr-108 4.99
(PDB ID: 3LFM) Tyr-106 1.79 His-231 3.90
Arg-96 2.75 -
Malaria Thr-217 1.89 Val-78 5.10
(PDB ID: 1SME) Asp-34 1.75 -
Figure 1  2D structure of Syringic acid
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Figure 2  Ligand interaction diagram of syringic acid with selected receptors. a) Syringic acid with 3ERT; 
b) Syringic acid with 1KPI; c) Syringic acid with 4IVT; d) Syringic acid with 3LFM; e) Syringic 
acid with 1SME
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distribution, metabolism and excretion based 
on Lipinski’s rule of five and exhibited good 
oral bioavailability. In addition, the compound 
is considered to be safe as it does not show any 
mutagenicity or carcinogenicity through toxicity 
analysis.
CONCLUSION
In conclusion, the docking study of syringic acid 
with several targets revealed that it is a promising 
candidate against selected diseases. It showed good 
docking scores comparing to the standard drugs. 
Also syringic acid has an acceptable druglike prop-
erty with no carcinogenicity or mutagenicity. Thus 
it can be considered for further in vitro and in vivo 
analysis of therapeutic potentials.
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